Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,054.32 +35.93 (+0.72%) Dow
38,153.74 +250.45 (+0.66%) Nasdaq
15,794.34 +188.86 (+1.21%) Bitcoin USD
59,125.56 +2,104.75 (+3.69%) CMC Crypto 200
1,271.81 +1.07 (+0.08%)
NovoCure Limited (NVCR)
| Previous close | 12.74 |
| Open | 13.39 |
| Bid | 12.80 x 400 |
| Ask | 12.90 x 100 |
| Day's range | 12.17 - 13.45 |
| 52-week range | 10.87 - 83.60 |
| Volume | |
| Avg. volume | 1,289,957 |
| Market cap | 1.383B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
ROOT, Switzerland, May 02, 2024--Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocure’s
- Business Wire
Novocure Reports First Quarter 2024 Financial Results
ROOT, Switzerland, May 02, 2024--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
- Business Wire
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
ROOT, Switzerland, April 24, 2024--Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4.
